Pacira BioSciences (NASDAQ:PCRX) Stock

PACIRA BIOSCIENCES INC

Pacira BioSciences

Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.

Pacira BioSciences Inc

-- Early clinical data indicates that Pre-existing and treatment-induced anti-Ad5 neutralizing antibodies do not impact the safety and effectiveness of PCRX-201 –
-- An oral presentation of the data to be featured at the ASGCT Annual Meeting --
BRISBANE, Calif., May 15, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCRX#NASDAQ">PCRX</a>), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients, today announced new preliminary data which suggests that clinical immunogenicity does not reduce sustained improvements in knee pain, stiffness and function provided by its gene therapy candidate, PCRX-201 (enekinragene inzadenovec), following local administration in patients with mild, moderate, as well as severe osteoarthritis of the knee. The research findings are being presented during a podium session at the American Society of Gene &amp; Cell Therapy (ASGCT) Annual Meeting in New Orleans on May 15, 2025, at 2:15 CT.

News

PCRX

Pacira Biosciences: New Preliminary Data Suggests Clinical Immunogenicity Does Not Reduce Sustained Improvements In Knee Pain, Stiffness And Function Provided By Gene Therapy Candidate, PCRX-201

Pacira BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCRX#NASDAQ">PCRX</a>) has been analyzed by 6 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">5</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $42.17, a high estimate of $70.00, and a low estimate of $24.00. Observing a 17.14% increase, the current average has risen from the previous average price target of $36.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1746795627_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The standing of Pacira BioSciences among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Serge Belanger</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$30.00</td>
<td>$32.00</td>
</tr>
<tr>
<td>Serge Belanger</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$32.00</td>
<td>$32.00</td>
</tr>
<tr>
<td>Oren Livnat</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$65.00</td>
<td>$48.00</td>
</tr>
<tr>
<td>Balaji Prasad</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$24.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>Serge Belanger</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$32.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Oren Livnat</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$70.00</td>
<td>$57.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Pacira BioSciences. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Pacira BioSciences compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Pacira BioSciences's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Pacira BioSciences's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/PCRX/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Pacira BioSciences analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Discovering Pacira BioSciences: A Closer Look</h2>
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
<h3>A Deep Dive into Pacira BioSciences's Financials</h3>
Market Capitalization Analysis: The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.
Revenue Growth: Pacira BioSciences's remarkable performance in 3M is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of 3.32%. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Pacira BioSciences's net margin is impressive, surpassing industry averages. With a net margin of 8.57%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 2.1%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 1.04%, the company showcases effective utilization of assets.
Debt Management: Pacira BioSciences's debt-to-equity ratio is below the industry average at 0.82, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Analyst Ratings: What Are They?</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

Where Pacira BioSciences Stands With Analysts

Needham analyst Serge Belanger maintains Pacira BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCRX#NASDAQ">PCRX</a>) with a Buy and lowers the price target from $32 to $30.

Price Target

Needham Maintains Buy on Pacira BioSciences, Lowers Price Target to $30

Pacira BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCRX#NASDAQ">PCRX</a>) affirms FY2025 sales outlook from $725.00 million-$765.00 million to $725.00 million-$765.00 million vs $752.21 million estimate.

Guidance

Pacira BioSciences Affirms FY2025 Sales Guidance of $725.00M-$765.00M vs $752.21M Est

Pacira BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCRX#NASDAQ">PCRX</a>) reported quarterly earnings of $0.62 per share which beat the analyst consensus estimate of $0.60 by 3.33 percent. This is unchanged from the same period last year. The company reported quarterly sales of $168.92 million which missed the analyst consensus estimate of $176.03 million by 4.03 percent. This is a 1.08 percent increase over sales of $167.12 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

Pacira BioSciences Q1 Adj. EPS $0.62 Beats $0.60 Estimate, Sales $168.92M Miss $176.03M Estimate

AAOI

ABCL

ABEV

ACIC

ACIW

ACMR

ACTG

AFRM

AKAM

AKBA

ALGM

ALIT

ALRM

ALXO

Amplify YieldShares Oil Hedged MLP Income ETF

AMLX

AMPX

AMTX

APPN

APYX

AQMS

ARGX

ARHS

ARKO

ARLO

ASPN

ASTH

Adtalem Global Education Inc. Common Stock

ATGE

ATHM

ATUS

AUTL

AVAH

AVPT

AXGN

BAER

BBDC

BIGC

BILL

BIRD

BlackSky Technology Inc. Class A Common Stock

BKSY

BLFS

BLND

CARG

CARS

CBLL

CBUS

CCEC

CCOI

CCRD

CDTX

CION

CLAR

CLFD

CLNE

CLSK

CMPS

CMRE

CODX

COIN

COLD

COLL

COMP

CRNX

CRON

CROX

CRVS

CTEV

CTKB

CTLP

CVRX

DAVE

DCGO

DCTH

DIOD

DKNG

Earnings Scheduled For May 8, 2025

Pacira BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCRX#NASDAQ">PCRX</a>) is gearing up to announce its quarterly earnings on Thursday, 2025-05-08. Here's a quick overview of what investors should know before the release.
Analysts are estimating that Pacira BioSciences will report an earnings per share (EPS) of $0.60.
Pacira BioSciences bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Historical Earnings Performance</h3>
During the last quarter, the company reported an EPS beat by $0.08, leading to a 5.24% drop in the share price on the subsequent day.
Here's a look at Pacira BioSciences's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.83</td>
<td>0.70</td>
<td>0.70</td>
<td>0.62</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.91</td>
<td>0.79</td>
<td>0.89</td>
<td>0.62</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-5.0%</td>
<td>0.0%</td>
<td>6.0%</td>
<td>12.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1746626586_0.png" alt="eps graph" />
<h3>Pacira BioSciences Share Price Analysis</h3>
Shares of Pacira BioSciences were trading at $25.15 as of May 06. Over the last 52-week period, shares are down 16.06%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. 
<h3>Analysts' Perspectives on Pacira BioSciences</h3>
Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on Pacira BioSciences.
Pacira BioSciences has received a total of 5 ratings from analysts, with the consensus rating as Buy. With an average one-year price target of $44.6, the consensus suggests a potential 77.34% upside.
<h3>Peer Ratings Comparison</h3>
The following analysis focuses on the analyst ratings and average 1-year price targets of Ocular Therapeutix, Amphastar Pharma and Innoviva, three prominent industry players, providing insights into their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Buy trajectory for Ocular Therapeutix, with an average 1-year price target of $15.83, suggesting a potential 37.06% downside.</li>
<li>Analysts currently favor an Neutral trajectory for Amphastar Pharma, with an average 1-year price target of $32.0, suggesting a potential 27.24% upside.</li>
<li>Analysts currently favor an Outperform trajectory for Innoviva, with an average 1-year price target of $55.0, suggesting a potential 118.69% upside.</li>
</ul>
<h3>Overview of Peer Analysis</h3>
In the peer analysis summary, key metrics for Ocular Therapeutix, Amphastar Pharma and Innoviva are highlighted, providing an understanding of their respective standings within the industry and offering insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pacira BioSciences</td>
<td>Buy</td>
<td>3.32%</td>
<td>$147.37M</td>
<td>2.10%</td>
</tr>
<tr>
<td>Ocular Therapeutix</td>
<td>Buy</td>
<td>15.41%</td>
<td>$15.85M</td>
<td>-14.50%</td>
</tr>
<tr>
<td>Amphastar Pharma</td>
<td>Neutral</td>
<td>4.73%</td>
<td>$86.65M</td>
<td>5.20%</td>
</tr>
<tr>
<td>Innoviva</td>
<td>Outperform</td>
<td>6.95%</td>
<td>$84.64M</td>
<td>2.99%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Pacira BioSciences ranks at the top for Revenue Growth among its peers. It is in the middle for Gross Profit. For Return on Equity, it is at the bottom compared to its peers.
<h3>Unveiling the Story Behind Pacira BioSciences</h3>
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
<h3>A Deep Dive into Pacira BioSciences's Financials</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: Pacira BioSciences displayed positive results in 3 months. As of 31 December, 2024, the company achieved a solid revenue growth rate of approximately 3.32%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 8.57%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Pacira BioSciences's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 2.1% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 1.04%, the company showcases effective utilization of assets.
Debt Management: With a below-average debt-to-equity ratio of 0.82, Pacira BioSciences adopts a prudent financial strategy, indicating a balanced approach to debt management.
<a href="https://www.benzinga.com/quote/PCRX/earnings">To track all earnings releases for Pacira BioSciences visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Preview: Pacira BioSciences's Earnings

Pacira BioSciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCRX#NASDAQ">PCRX</a>), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced new data from its ongoing Phase 1 study of its gene therapy candidate PCRX-201 (enekinragene inzadenovec). The <a href="https://www.globenewswire.com/Tracker?data=sPdlu4TKNZIsHxJEPTmy6FyLva5Ge3rx5UPKl7XVfE1YRsdxrAIFmq309CL0nLPgSv5WPaX_spBjEwC4uQ0KrXWNYhbirikskfe1qcEqzwA1spXxBsqKL5KGOb_P-6tAG9llQx0-2dMk6HuG_sP9Mg==">data</a> is being presented at the 2025 European Alliance of Associations for Rheumatology (EULAR) Annual Congress, taking place from June 11-14, in Barcelona, Spain.
Presentation Title: A Single Intra-articular Injection of the Gene Therapy PCRX-201 Was Safe and Provided Sustained Clinical Benefits for Patients With Moderate-to-Severe Knee Osteoarthritis Through 3 Years
Presented By:&nbsp;Philip G. Conaghan, MB BS, PhD, FRACP, FRCP, Professor of Musculoskeletal Medicine, University of Leeds, UK; Director, NIHR Leeds Biomedical Research Centre
Date &amp; Time:&nbsp;Wednesday, June 11 from 3:30 pm – 4:30 pm CEST
About PCRX-201 (enekinragene inzadenovec)
PCRX-201 (enekinragene inzadenovec) features an innovative design based on the company's proprietary high-capacity adenovirus vector platform. It is currently being studied in the fundamental, underlying chronic inflammatory processes that contribute to "wear and tear" over time in osteoarthritis of the knee, a condition that affects more than 14 million individuals in the U.S. today.
In November 2024, Pacira reported promising data from a large Phase 1 study in which PCRX-201 provided sustained improvements in knee pain, stiffness, and function through two years following local administration, with a well-tolerated safety profile. PCRX-201 has received Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. Food and Drug Administration and Advanced Therapy Medicinal Products (ATMP) designation from the European Medicines Agency. PCRX-201 is the first gene therapy to achieve these clinical results and earn these regulatory designations in osteoarthritis of the knee – a testament to its promise and potential.
Given the promising Phase 1 results, dosing is underway in a <a href="https://www.globenewswire.com/Tracker?data=c5NTS41A9eCJ7pBJDDcVdJl24zDQ5oUQhkXsBarkSENehjkVqxb0mhTlMeR5u4B7txnhAtd41I7RLfCjuDRiXFhwWkEBcDMKQHyg8vlFrIwBmchK9b3nYcwRh1gXCofoiDNQMJEIg-iG8nJw9v___I0HqteHZCvRV6-8wlVVtXa7_cI3BW3Z5F5OoIk_nnTui40yJ0FtHb2t5a5UtEGUCA==">Phase 2</a> study of PCRX-201 (<a href="https://www.globenewswire.com/Tracker?data=D7wLILMMFqdRJlncOrA56lLJsP-QFY5_wdKYIc0-vFYnSmm7GREJ9AszWQrwKWsaS5a4ofVFOHFPsbSZ8A4vlIjs4Lp2YB5KIg7oToeMTAoKdgzvR2muxJugdGtfhrXD_pzvzD_2Wtmdk_DRSzZfAQ==">the ASCEND study</a>) for the treatment of knee osteoarthritis. To learn more about PCRX-201 and the company's <a href="https://www.globenewswire.com/Tracker?data=DRcDeFIJ6lfhc-n94dMXJV9ZiqcHotiJw1VqdV1Csb3Nc1uPEkfNLWcfH_LupAU2OV7bdqpyZOQ7z5aWzAwYOi4AkEacArJ_0iQ9nrmknA8PmRXm_KnSRN_gmzDzuSjde1kjylIKxDK8cmlBkVvnCRftWCyl141-C6uywhgTdT4iyQgLzhDbX9ozD6e7PpYlrx9vzdOzKtei275ETd12wA==">clinical development program</a>, please visit the <a href="https://www.globenewswire.com/Tracker?data=qS5LfB_Ae7WfmI8YxuxgI8hoWWUGsoIFRbve7Blmz5ZVzc4MG-BOQjBmk4NWlB1YP0eQF0m6UDkgPuLGO6rg6FW9KDGNsZIU8ae0PMEjRSA=">investor events</a> section of the company's investor website.

Biotech

General

Pacira BioSciences Announces It Will Present 3-Year Safety And Efficacy Data of PCRX-201 Following Single Intra-Articular Injection For Moderate-to-Severe Knee Osteoarthritis At 2025 European Alliance Of Associations For Rheumatology June 11-14 2025 In Barcelona, Spain

Pacira BioSciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCRX#NASDAQ">PCRX</a>), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced an upcoming podium presentation of findings from its Phase 1 study of PCRX-201 (enekinragene inzadenovec), a locally administered gene therapy candidate for osteoarthritis of the knee. The data will be presented at the 28th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) in New Orleans on May 15. The presentation will highlight how preexisting and treatment-induced neutralizing antibodies (NAbs) impact the therapy's efficacy, safety, and redosing potential.

Pacira BioSciences To Present Findings From Phase 1 Study Of PCRX-201 And Its Implications For Dosing Strategy In Knee Osteoarthritis At ASGCT Annual Meeting

- PCRX-201 demonstrated two years of clinically meaningful improvements in pain, stiffness and function across all structural severity subgroups, including advanced disease --
-- Study Findings Presented at 2025 OARSI World Congress--
BRISBANE, Calif., April 28, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCRX#NASDAQ">PCRX</a>), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced new data demonstrating its locally administered gene therapy candidate, PCRX-201 (enekinragene inzadenovec), provided sustained improvements in knee pain, stiffness, and function for up to two years following a single local administration in patients with mild, moderate, as well as severe osteoarthritis of the knee. The data was presented during a poster session at the 2025 Osteoarthritis Research Society International (OARSI) World Congress in Incheon, South Korea, on Friday, April 25, and Saturday, April 26.

Pacira BioSciences Announces 2-Yr Data On PCRX-201 Gene Therapy Demonstrating Sustained Knee Pain Relief

-- Poster to be presented at OARSI World Congress on Osteoarthritis --

Events

Pacira BioSciences To Present 104-Week Data Of PCRX-201 For Patients With Mild To Severe Osteoarthritis Of Knee

U.S. stocks were lower, with the Dow Jones index falling around 700 points on Monday.
Shares of Wolverine World Wide, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WWW#NYSE">WWW</a>) rose sharply during <a href="https://www.benzinga.com/quote/WWW/analyst-ratings">Monday's session</a>.
Baird analyst Jonathan Komp upgraded the rating for Wolverine World Wide from Neutral to Outperform.
Wolverine World Wide shares jumped 7.2% to $11.56 on Monday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>Verve Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERV#NASDAQ">VERV</a>) jumped 15% to $5.28. Cantor Fitzgerald analyst Rick Bienkowski, on April 15, upgraded Verve Therapeutics from Neutral to Overweight.</li>
<li>Waton Financial Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WTF#NASDAQ">WTF</a>) gained 14.8% to $7.43.</li>
<li>uniQure N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QURE#NASDAQ">QURE</a>) shares rose 12.4% to $14.61. uniQure was recently granted FDA granted Breakthrough Therapy designation for AMT-130 for the treatment of Huntington&#8217;s disease.</li>
<li>Intellia Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTLA#NASDAQ">NTLA</a>) gained 12% to $8.10.</li>
<li>Rocket Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RCKT#NASDAQ">RCKT</a>) climbed 11.4% to $7.05.</li>
<li>Erasca, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ERAS#NASDAQ">ERAS</a>) climbed 11.2% to $1.2900.</li>
<li>Microvast Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MVST#NASDAQ">MVST</a>) rose 11% to $2.0324.</li>
<li>Beam Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAM#NASDAQ">BEAM</a>) gained 10.6% to $18.81.</li>
<li>Replimune Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REPL#NASDAQ">REPL</a>) shares gained 9.6% to $8.76.</li>
<li>Pacira BioSciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCRX#NASDAQ">PCRX</a>) shares rose 6.3% to $26.21 as the company announced a $300 million share repurchase program.</li>
<li>CleanSpark, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLSK#NASDAQ">CLSK</a>) gained 5.3% to $7.90.</li>
<li>B2Gold Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BTG#NYSE">BTG</a>) gained 4.8% to $3.4800.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44896269/how-to-earn-500-a-month-from-3m-stock-ahead-of-q1-earnings">How To Earn $500 A Month From 3M Stock Ahead Of Q1 Earnings</a> </li>
</ul>
Photo via Shutterstock

Intraday Update

Markets

Movers

Trading Ideas

BEAM

ERAS

MVST

NTLA

QURE

RCKT

REPL

VERV

Wolverine World Wide, Pacira BioSciences And Other Big Stocks Moving Higher On Monday

Pacira BioSciences Announces $300M Share Repurchase Program

Pacira BioSciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCRX#NASDAQ">PCRX</a>) on Monday settled its litigations with Fresenius Kabi USA, Jiangsu Hengrui Pharmaceuticals Co., Ltd., and eVenus Pharmaceuticals Laboratories, Inc. related to patents for Exparel (bupivacaine <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">liposome injectable suspension)</a>.
Exparel is Pacira BioSciences' non-opioid analgesic pain management and is indicated for postsurgical analgesia.
As part of the settlement, the parties will file Consent Judgments with the United States Court of Appeals for the Federal Circuit and the United States District Courts for the District of New Jersey and the Northern District of Illinois that enjoin Fresenius from marketing generic bupivacaine liposome injectable suspension before the expiration of the <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/g44674361/pacira-biosciences-announces-settlement-of-u-s-patent-litigation-for-exparel" rel="noreferrer noopener">patents-in-suit</a>.
In settlement of all outstanding claims in the litigations, Pacira has agreed to provide Fresenius with a license to Pacira&#8217;s patents required to manufacture and sell certain volume-limited amounts of generic bupivacaine liposome injectable suspension in the U.S. beginning on a confidential date that is sometime in early 2030.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/01/42854744/pacira-biosciences-secures-fda-approval-for-new-iovera-smarttip-to-manage-chronic-low-back-pain" rel="noreferrer noopener">Pacira BioSciences Secures FDA Approval For New iovera SmartTip to Manage Chronic Low Back Pain</a>
The license will permit generic bupivacaine liposome injectable suspension entry before the July 2, 2044, expiration date of the last-to-expire of Pacira&#8217;s Orange Book-listed patents for Exparel.
While the agreed-upon volume-limited percentages are confidential, they begin at a high-single-digit percentage of the total volumes distributed in the U.S. market and increase gradually in each 12-month period following the volume-limited entry date until reaching a percentage in the low thirties in 2033 and increasing modestly in each of the next two 12-month periods before reaching a maximum percentage in the high thirties of the total volumes distributed in the U.S. for the final three years of the agreement.
In addition, Pacira has agreed to provide Fresenius with a license to Pacira&#8217;s patents required to manufacture and sell an unlimited quantity of generic bupivacaine liposome injectable suspension in the U.S. beginning no earlier than 2039.
In an SEC <a href="https://www.benzinga.com/secfilings/25/04/44674982/pacira-biosciences-inc-general-corporate-statement-form8" target="_blank" rel="noreferrer noopener">filing</a>, the company&#8217;s expected savings concerning, among other things, the avoidance of the fees, costs, time and resources associated with continuing the Litigations, the company will pay the Fresenius Parties $7.0 million.
Exparel net product sales were $147.7 million in the fourth quarter of 2024, a 3% <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/g44024616/pacira-biosciences-reports-fourth-quarter-and-full-year-2024-financial-results" rel="noreferrer noopener">year over year increase</a>.
In August 2024, Pacira BioSciences announced that the U.S. District Court for the District of New Jersey found that the company's U.S. Patent No. 11,033,495 (the ‘495 patent)&nbsp;<a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/08/40321378/pain-management-focused-pacira-biosciences-loses-patent-fight-for-key-drug-jp-morga" rel="noreferrer noopener">is not valid</a>.
In November 2021, Pacira BioSciences&nbsp;<a target="_blank" href="https://investor.pacira.com/news-releases/news-release-details/pacira-files-lawsuit-against-evenus-patent-infringement?tblci=GiCUX7wvU_AgmIIiQduNYr6JQuJQLy6SZJGvpyeZuCzyqiCN1VcoxvTN4f7-y-PqATDviEo" rel="noreferrer noopener">filed</a>&nbsp;a lawsuit in the United States District Court for the District of New Jersey against&nbsp;eVenus Pharmaceutical Laboratories for patent infringement of U.S. Patent Number 11,033,495.
Analyst Reaction:
<ul>
<li>HC Wainwright maintains Pacira BioSciences with a Buy, raising the price target <a href="https://www.benzinga.com/quote/PCRX/analyst-ratings" target="_blank" rel="noreferrer noopener">from $48 to $65</a>.</li>
<li>Needham reiterates Pacira BioSciences with a Buy and maintains a price target of $32.</li>
</ul>
Price Action: PCRX stock is up 16.8% at $26.77 at the last check on Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/health-care/25/04/44685591/walgreens-boots-alliance-q2-earnings-beats-expectations-suspends-guidance-amid-pending-private-equity-deal-with-sycamore-partners" target="_blank" rel="noreferrer noopener">Walgreens Boots Alliance Q2 Profit Falls 47.5%, Suspends Guidance On Pending Private Equity Deal</a></li>
</ul>
Photo: Shutterstock

Health Care

Legal

Pacira Settles Patent Dispute Over Exparel With Fresenius, Delays Pain Med' Generics Entry Until 2030, Stock Jumps

U.S. stocks were higher, with the Dow Jones index surging over 1,300 points on Tuesday.
Shares of Marvell Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVL#NASDAQ">MRVL</a>) rose sharply during Tuesday's session after Infineon Technologies agreed to acquire its Automotive Ethernet <a href="https://in.benzinga.com/25/04/44683383/marvell-plays-ai-hardball-divestiture-sparks-155-upside-says-analyst">Business for $2.5 billion in cash</a>.
The transaction includes Marvell&#8217;s Brightlane Automotive Ethernet portfolio and related assets. The company projected this segment to generate $225 million to $250 million in revenue in 2025, with a gross margin of around 60%.
Marvell Technology shares jumped 10.1% to $56.16 on Tuesday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>agilon health, inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AGL#NYSE">AGL</a>) shares jumped 31.8% to $5.60.</li>
<li>NextDecade Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEXT#NASDAQ">NEXT</a>) gained 23.3% to $7.38 after the company announced a 20-year LNG sale and purchase agreement to supply 1.2 million tonnes per year to a subsidiary of Saudi Aramco.</li>
<li>Venture Global, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VG#NYSE">VG</a>) gained 21.4% to $8.50.</li>
<li>CorMedix Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRMD#NASDAQ">CRMD</a>) shares rose 21.1% to $7.36 after the company issued first-quarter preliminary revenue guidance above estimates.</li>
<li>Pacira BioSciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCRX#NASDAQ">PCRX</a>) gained 16.1% to $26.60 after HC Wainwright &amp; Co. raised its price target on the stock from $48 to $65 and maintained a Buy rating.</li>
<li>Alignment Healthcare, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALHC#NASDAQ">ALHC</a>) jumped 14.9% to $20.48.</li>
<li>Uxin Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UXIN#NASDAQ">UXIN</a>) gained 14.7% to $3.9098.</li>
<li>Carvana Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVNA#NYSE">CVNA</a>) climbed 14.6% to $192.29.</li>
<li>Applied Optoelectronics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAOI#NASDAQ">AAOI</a>) rose 14% to $12.81.</li>
<li>ECARX Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ECX#NASDAQ">ECX</a>) gained 14% to $1.14 after the company announced it increased its share repurchase program by $20 million to $40 million.</li>
<li>Humana Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) rose 12.3% to $286.14 following a WSJ report indicating the Trump administration will increase Medicare Advantage rates.</li>
<li>Rhythm Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RYTM#NASDAQ">RYTM</a>) gained 12.4% to $61.76. Canaccord Genuity analyst Whitney Ijem maintained Rhythm Pharmaceuticals with a Buy and raised the price target from $81 to $92.</li>
<li>Grab Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRAB#NASDAQ">GRAB</a>) rose 12.4% to $3.9150.</li>
<li>Sandisk Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNDK#NASDAQ">SNDK</a>) gained 12.4% to $35.40.</li>
<li>Western Digital Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WDC#NASDAQ">WDC</a>) rose 10% to $34.26.</li>
<li>AppLovin Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APP#NASDAQ">APP</a>) gained 10% to $255.36.</li>
<li>CVS Health Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) rose 8.5% to $69.29 after the company announced changes to management and Medicare increased advantage payment rates.</li>
<li>NVIDIA Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) gained 7.9% to $105.39.</li>
<li>Shopify Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHOP#NYSE">SHOP</a>) rose 7.8% to $85.05.</li>
<li>Tesla, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) gained 6.3% to $248.09.</li>
<li>Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) rose 4.2% to $189.13. U.S. consumers are reportedly rushing to Apple stores to purchase new iPhones ahead of potential price hikes caused by President Donald Trump&#8217;s newly announced tariffs on Chinese imports.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/04/44682968/how-to-earn-500-a-month-from-delta-air-lines-stock-ahead-of-q1-earnings">How To Earn $500 A Month From Delta Air Lines Stock Ahead Of Q1 Earnings</a> </li>
</ul>
Photo via Shutterstock

AAPL

ALHC

CRMD

CVNA

GRAB

MRVL

NVDA

RYTM

SHOP

SNDK

TSLA

UXIN

Marvell Technology, Nvidia, Tesla, Apple And Other Big Stocks Moving Higher On Tuesday

Ratings for Pacira BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCRX#NASDAQ">PCRX</a>) were provided by 8 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">5</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Pacira BioSciences, presenting an average target of $37.0, a high estimate of $70.00, and a low estimate of $18.00. This current average has increased by 27.59% from the previous average price target of $29.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1744120826_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Pacira BioSciences. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Serge Belanger &#x7C;Needham &#x7C;Maintains &#x7C;Buy &#x7C; $32.00&#x7C;$32.00 &#x7C; 
&#x7C;Oren Livnat &#x7C;HC Wainwright &amp; Co. &#x7C;Raises &#x7C;Buy &#x7C; $65.00&#x7C;$48.00 &#x7C; 
&#x7C;Balaji Prasad &#x7C;Barclays &#x7C;Raises &#x7C;Overweight &#x7C; $24.00&#x7C;$17.00 &#x7C; 
&#x7C;Serge Belanger &#x7C;Needham &#x7C;Raises &#x7C;Buy &#x7C; $32.00&#x7C;$30.00 &#x7C; 
&#x7C;Oren Livnat &#x7C;HC Wainwright &amp; Co. &#x7C;Raises &#x7C;Buy &#x7C; $70.00&#x7C;$57.00 &#x7C; 
&#x7C;Les Sulewski &#x7C;Truist Securities &#x7C;Raises &#x7C;Hold &#x7C; $25.00&#x7C;$8.00 &#x7C; 
&#x7C;Gregory Renza &#x7C;RBC Capital &#x7C;Maintains &#x7C;Sector Perform &#x7C; $18.00&#x7C;$18.00 &#x7C; 
&#x7C;Serge Belanger &#x7C;Needham &#x7C;Raises &#x7C;Buy &#x7C; $30.00&#x7C;$22.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Pacira BioSciences. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Pacira BioSciences compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Capture valuable insights into Pacira BioSciences's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/PCRX/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Pacira BioSciences analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Unveiling the Story Behind Pacira BioSciences</h2>
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
<h3>Financial Insights: Pacira BioSciences</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Growth: Over the 3M period, Pacira BioSciences showcased positive performance, achieving a revenue growth rate of 3.32% as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 8.57%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Pacira BioSciences's ROE stands out, surpassing industry averages. With an impressive ROE of 2.1%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Pacira BioSciences's ROA stands out, surpassing industry averages. With an impressive ROA of 1.04%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Pacira BioSciences's debt-to-equity ratio is below the industry average. With a ratio of 0.82, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>Analyst Ratings: Simplified</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Forecasting The Future: 8 Analyst Projections For Pacira BioSciences

WIIM

Pacira BioSciences shares are trading higher after HC Wainwright & Co. raised its price target on the stock from $48 to $65 and maintained a Buy rating.

Needham analyst Serge Belanger reiterates Pacira BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCRX#NASDAQ">PCRX</a>) with a Buy and maintains $32 price target.

Reiteration

Needham Reiterates Buy on Pacira BioSciences, Maintains $32 Price Target

<h3>Gainers</h3>
<ul>
<li>NanoVibronix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAOV#NASDAQ">NAOV</a>) shares increased by 190.8% to $8.55 during Tuesday's pre-market session. The company's market cap stands at $6.4 million. </li>
<li>Psyence Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBM#NASDAQ">PBM</a>) stock moved upwards by 32.42% to $0.58. The market value of their outstanding shares is at $2.6 million. </li>
<li>60 Degrees (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SXTP#NASDAQ">SXTP</a>) stock rose 32.33% to $2.38. The company's market cap stands at $3.5 million. </li>
<li>NAYA Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAYA#NASDAQ">NAYA</a>) shares moved upwards by 27.36% to $2.67. The company's market cap stands at $13.1 million. </li>
<li>Mainz Biomed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYNZ#NASDAQ">MYNZ</a>) stock increased by 22.32% to $3.89. The company's market cap stands at $8.6 million. </li>
<li>Pacira BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCRX#NASDAQ">PCRX</a>) shares increased by 20.07% to $27.51. The market value of their outstanding shares is at $1.2 billion. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Bluejay Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BJDX#NASDAQ">BJDX</a>) stock decreased by 51.2% to $3.66 during Tuesday's pre-market session. The market value of their outstanding shares is at $2.0 million. </li>
<li>Performant Healthcare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHLT#NASDAQ">PHLT</a>) stock decreased by 46.37% to $1.4. The market value of their outstanding shares is at $109.6 million. </li>
<li>CVRx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVRX#NASDAQ">CVRX</a>) stock declined by 30.25% to $8.05. The company's market cap stands at $209.5 million. </li>
<li>Impact BioMedical (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/IBO#AMEX">IBO</a>) shares fell 19.02% to $0.7. The company's market cap stands at $8.0 million. </li>
<li>Protagenic Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTIX#NASDAQ">PTIX</a>) shares declined by 16.44% to $0.27. The company's market cap stands at $2.0 million. </li>
<li>Shattuck Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STTK#NASDAQ">STTK</a>) stock decreased by 16.17% to $1.09. The market value of their outstanding shares is at $52.2 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BJDX

MYNZ

NAOV

NAYA

PHLT

PTIX

STTK

SXTP

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

HC Wainwright &amp; Co. analyst Oren Livnat maintains Pacira BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCRX#NASDAQ">PCRX</a>) with a Buy and raises the price target from $48 to $65.

HC Wainwright & Co. Maintains Buy on Pacira BioSciences, Raises Price Target to $65

Press Releases

Pacira BioSciences Announces Two-Year Efficacy Data Following a Single Local Administration of PCRX-201 in Patients with Mild to Severe Osteoarthritis of the Knee

Pacira to Report First Quarter 2025 Financial Results on Thursday May 8, 2025

Pacira BioSciences to Present New Data on Clinical Immunogenicity of Intra-Articular PCRX-201 and Its Implications for Dosing Strategy in Knee Osteoarthritis

Pacira BioSciences to Present 3-Year Safety and Efficacy Data of PCRX-201 Following Single Intra-Articular Injection for Moderate-to-Severe Knee Osteoarthritis

Pacira BioSciences Reports First Quarter 2025 Financial Results

Lawsuit for Investors in shares of Pacira BioSciences, Inc. (NASDAQ: PCRX) announced by the Shareholders Foundation

Pacira BioSciences to Participate in Fireside Chat at Two Upcoming Healthcare Conferences

Pacira BioSciences Presents New Data on the Effects of Clinical Immunogenicity on Locally Administered PCRX-201 in Patients with Moderate to Severe Osteoarthritis of the Knee

Grabar Law Office Investigates Claims on Behalf of Shareholders of DoubleVerify Holdings, Inc. (NYSE: DV); NAPCO Securities Technologies, Inc. (NASDAQ: NSSC); Pacira Biosciences, Inc. (NASDAQ: PCRX); and Treace Medical Concepts, Inc. (NASDAQ: TMCI)

Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Comments

Pacira BioSciences

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL